Developing a long-lasting treatment for methamphetamine addiction
IND-enabling program for a long-acting anti-methamphetamine monoclonal antibody for treating methamphetamine use disorder
This study is working on a new treatment for people with methamphetamine use disorder by developing a special antibody that can help lessen the effects of the drug, making it easier for them to stick to their recovery plan.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Intervexion Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Little Rock, United States) |
| Project ID | NIH-10890735 on NIH RePORTER |
What this research studies
This research focuses on creating a monoclonal antibody that can help treat methamphetamine use disorder (MUD) by reducing the drug's effects in the body. The approach involves developing a long-acting antibody that can be administered less frequently, potentially improving patient compliance with treatment. The research will include preclinical testing in animal models to identify the most effective antibody candidate before moving to human trials. If successful, this treatment could provide a new option for individuals struggling with MUD.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with methamphetamine use disorder who are seeking treatment.
Not a fit: Patients who do not have a methamphetamine use disorder or those who are not seeking treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could offer a new, effective treatment option for individuals with methamphetamine use disorder.
How similar studies have performed: Previous research has shown promise with anti-METH antibodies in animal models, but this approach is still in the development phase for human application.
Where this research is happening
Little Rock, United States
- Intervexion Therapeutics, LLC — Little Rock, United States (Active)
Researchers
- Principal investigator: Stevens, Misty Ward — Intervexion Therapeutics, LLC
- Study coordinator: Stevens, Misty Ward
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.